UBC finalizes first global access agreement for a new therapy

Earlier this month, UBC announced that the license agreement for Dr. Kishor Wasan’s new oral formulation of anti-fungal and anti-Leishmania drug Amphotericin B has been finalized. The agreement with iCo Therapeutics Inc. includes mechanisms to promote the availability of the drug in low- and middle-income countries, and is the first global access agreement on a new drug to be executed under UBC’s new global access principles. We at UAEM think that UBC deserves enthusiastic congratulations for its efforts on this project!

Read more in UBC’s press release.

Advertisements

One response to “UBC finalizes first global access agreement for a new therapy

  1. I very sporadically write remarks, nonetheless I looked through a
    lot of reviews here at UBC finalizes first global access agreement for a new therapy | Universities Allied for Essential
    Medicines – UBC chapter and had a couple of questions for you if you do not mind.

    Is this just me or are a number of of the above
    comments look as if they are just plain generated from brain dead
    folks? As well, if you are article writing on other different websites, I want to stay in
    touch with you. Is it possible to post a listing of all
    of the social network pages including linkedin profile, Facebook page or twitter feed?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s